Research progress on the nucleoside/nucleotide-loaded nanomedicines
Nucleoside drugs play an essential role in treating major diseases such as tumor and viral infections, and have been widely applied in clinics. However, the effectiveness and application of nucleoside drugs are significantly limited by their intrinsic properties such as low bioavailability, lack of targeting ability, and inability to enter the cells. Nanocarriers can improve the physiological properties of nucleoside drugs by improving drug delivery efficiency and availability, maintaining drug efficacy and system stability, adjusting the binding ability of the carrier and drug molecules, as well as modifying specific molecules to achieve active targeting. Starting from the design strategy of nucleoside drug nanodelivery systems, the design and therapeutic effect of these nanomedicines are described in this review, and the future development directions of nucleoside/nucleotide-loaded nanomedicines are also discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences - 52(2023), 3 vom: 25. Juni, Seite 279-284 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
核苷类药物纳米递送系统研究进展 |
|---|
| Beteiligte Personen: |
Zhou, Zheng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastics |
|---|
| Anmerkungen: |
Date Completed 11.08.2023 Date Revised 28.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3724/zdxbyxb-2022-0701 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359773508 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359773508 | ||
| 003 | DE-627 | ||
| 005 | 20231226081606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3724/zdxbyxb-2022-0701 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359773508 | ||
| 035 | |a (NLM)37476939 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhou, Zheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Research progress on the nucleoside/nucleotide-loaded nanomedicines |
| 246 | 3 | 3 | |a 核苷类药物纳米递送系统研究进展 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.08.2023 | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Nucleoside drugs play an essential role in treating major diseases such as tumor and viral infections, and have been widely applied in clinics. However, the effectiveness and application of nucleoside drugs are significantly limited by their intrinsic properties such as low bioavailability, lack of targeting ability, and inability to enter the cells. Nanocarriers can improve the physiological properties of nucleoside drugs by improving drug delivery efficiency and availability, maintaining drug efficacy and system stability, adjusting the binding ability of the carrier and drug molecules, as well as modifying specific molecules to achieve active targeting. Starting from the design strategy of nucleoside drug nanodelivery systems, the design and therapeutic effect of these nanomedicines are described in this review, and the future development directions of nucleoside/nucleotide-loaded nanomedicines are also discussed | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antineoplastics | |
| 650 | 4 | |a Antiviral drugs | |
| 650 | 4 | |a Nanodrug delivery system | |
| 650 | 4 | |a Nucleoside analogue | |
| 650 | 4 | |a Nucleoside drugs | |
| 650 | 4 | |a Nucleotide | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Nucleosides |2 NLM | |
| 650 | 7 | |a Nucleotides |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 700 | 1 | |a Liu, Haifang |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Mingzhou |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences |d 2002 |g 52(2023), 3 vom: 25. Juni, Seite 279-284 |w (DE-627)NLM123207037 |x 1008-9292 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2023 |g number:3 |g day:25 |g month:06 |g pages:279-284 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3724/zdxbyxb-2022-0701 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2023 |e 3 |b 25 |c 06 |h 279-284 | ||